(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...
Stats | |
---|---|
आज की मात्रा | 892.00 |
औसत मात्रा | 5 243.00 |
बाजार मूल्य | 1.65B |
EPS | $0 ( 2024-03-07 ) |
अगली कमाई की तारीख | ( $0 ) 2024-05-14 |
Last Dividend | $0.593 ( 2020-03-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.66 |
ATR14 | $0 (0.00%) |
Bavarian Nordic A/S सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Bavarian Nordic A/S वित्तीय
Annual | 2023 |
राजस्व: | $7.06B |
सकल लाभ: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
राजस्व: | $7.06B |
सकल लाभ: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
राजस्व: | $0 |
सकल लाभ: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
राजस्व: | $3.15B |
सकल लाभ: | $1.70B (53.99 %) |
EPS: | $-4.93 |
Financial Reports:
No articles found.
Bavarian Nordic A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.593 | 2020-03-27 |
Last Dividend | $0.593 | 2020-03-27 |
Next Dividend | $0 | N/A |
Payout Date | 2020-04-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.593 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.27 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VDMCY | Ex Dividend Knight | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
KSBI | Ex Dividend Knight | 2023-07-28 | Quarterly | 0 | 0.00% | |
CGEMY | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% | |
SCGLY | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
FSUGY | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
AGESY | Ex Dividend Junior | 2023-10-25 | Annually | 0 | 0.00% | |
YATRF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
MONDY | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
CNLTP | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
STBI | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.74 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.57 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.153 | 1.500 | 9.41 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.938 | 0.800 | 5.31 | 4.25 | [1 - 3] |
quickRatioTTM | 1.342 | 0.800 | 6.81 | 5.45 | [0.8 - 2.5] |
cashRatioTTM | 0.530 | 1.500 | 8.17 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00430 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.16 | 1.000 | 1.793 | 1.793 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.08 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00597 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.652 | 1.000 | 2.47 | 2.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.215 | 1.000 | 7.70 | 7.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 18.15 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.492 | 0.800 | -0.0521 | -0.0416 | [0.5 - 2] |
Total Score | 10.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 2.55 | 1.000 | 9.84 | 0 | [1 - 100] |
returnOnEquityTTM | 0.153 | 2.50 | 9.62 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00228 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.54 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं